CELLDEX THERAPEUTICS INC, Friday close $14.16, +18.15 pct premarket Interim data showed the drugmaker’s brain tumor drug shrunk tumor, improved survival in patients without the disease worsening. Roth Capital raised its price …
NEEDHAM, Mass., Feb. 5, 2013 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced the pricing of an underwritten public offering of 12,000,000 shares of its common stock, offered at a price to the …
Pfizer has decided to terminate a brain cancer vaccine partnership with Celldex Therapeutics ... Investors have been less enthusiastic and the company's stock sank 26.2% to $3.53.
Hampton, NJ-based Celldex Therapeutics has become the latest beneficiary of that strategy through a deal today with Bristol-Myers Squibb. Celldex and Bristol-Myers said today that the two companies will work together to run a clinical …